MedTrace Logo

Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma

NCT04149275 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-02-21

No results posted yet for this study

Summary

The purpose of this study is to test the safety of Cabozantinib in combination with Nivolumab and Ipilimumab and see what affects that this combination treatment has on those with recurrent carcinosarcomas.

Conditions

  • Carcinosarcoma of Ovary
  • Carcinosarcoma of Uterus
  • Carcinosarcoma of Vagina

Interventions

DRUG

Cabozantinib

Treatment with oral Cabozantinib once daily

DRUG

Ipilimumab

IV administration of Ipilimumab on 21 day cycles

DRUG

Nivolumab

IV administration of Nivolumab on 21 day cycles, followed by Nivolumab maintenance on 28 day cycles

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Rebecca C Arend, MD, MSPH · University of Alabama at Birmingham

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-28
Primary Completion
2021-02-28
Completion
2021-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04149275 on ClinicalTrials.gov